drugset
drugset / Trial / NCT00566462

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

NCT00566462 ↗

Phase 2 Terminated 1 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a two-arm, double-blind, placebo-controlled study.

Timeline

Start
2007-10
Primary completion
2008-12-01
Completion
2008-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 4 mg —

Indications

Parkinson disease